Basmisanil
Basmisanil (INN; developmental codes RG-1662 and RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome.[1][2][3] As of June 2016, it is no longer studied.[4] It is studied with schizophrenia patients.[5]
Clinical data | |
---|---|
Other names | RG-1662; RO5186582 |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H20FN3O5S |
Molar mass | 445.47 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
See also
References
- Froestl W, Muhs A, Pfeifer A (2012). "Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors". J. Alzheimers Dis. 32 (4): 793–887. doi:10.3233/JAD-2012-121186. PMID 22886028.
- Hurley, Dan (2013). "Investigators Silence Trisomy 21 Chromosome in Human Down Syndrome Cells". Neurology Today. 13 (17): 14–15. doi:10.1097/01.NT.0000434604.55014.fd. ISSN 1533-7006.
- Rudolph, Uwe; Jensen, Henrik Sindal; Nichol, Kathryn; Lee, Deborah; Ebert, Bjarke (2014). "Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes". PLOS ONE. 9 (2): e88456. Bibcode:2014PLoSO...988456J. doi:10.1371/journal.pone.0088456. ISSN 1932-6203. PMC 3922815. PMID 24533090.
- Marly Chevrette. "Response to the Roche Clinical Trial for CLEMATIS". Retrieved 2016-06-28.
- "A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics". 21 January 2021. Retrieved 2021-07-02.
{{cite journal}}
: Cite journal requires|journal=
(help)CS1 maint: url-status (link)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.